

Douglas Yee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4017621/publications.pdf>

Version: 2024-02-01

224
papers

17,376
citations

13827

67
h-index

16127

124
g-index

228
all docs

228
docs citations

228
times ranked

19862
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes and Cancer. <i>Diabetes Care</i> , 2010, 33, 1674-1685.	4.3	1,618
2	APOBEC3B is an enzymatic source of mutation in breast cancer. <i>Nature</i> , 2013, 494, 366-370.	13.7	758
3	Diabetes and Cancer: A Consensus Report. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 207-221.	157.7	724
4	Adaptive Randomization of Veliparibâ€“Carboplatin Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 23-34.	13.9	467
5	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. <i>Journal of Clinical Investigation</i> , 2008, 118, 2609-19.	3.9	443
6	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 676.	3.4	419
7	Analysis of Insulin-Like Growth Factor I Gene Expression in Malignancy: Evidence for a Paracrine Role in Human Breast Cancer. <i>Molecular Endocrinology</i> , 1989, 3, 509-517.	3.7	387
8	Disrupting insulin-like growth factor signaling as a potential cancer therapy. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1-12.	1.9	339
9	Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. <i>Cancer Cell</i> , 2004, 5, 553-563.	7.7	318
10	In vivo quantification of choline compounds in the breast with ¹ H MR spectroscopy. <i>Magnetic Resonance in Medicine</i> , 2003, 50, 1134-1143.	1.9	317
11	Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer: Predicting Response with in Vivo ¹ H MR Spectroscopyâ€“A Pilot Study at 4 T. <i>Radiology</i> , 2004, 233, 424-431.	3.6	304
12	Adaptive Randomization of Neratinib in Early Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 11-22.	13.9	301
13	Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo. <i>Molecular Endocrinology</i> , 1999, 13, 787-796.	3.7	292
14	Randomized Controlled Trial of Weight Training and Lymphedema in Breast Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2006, 24, 2765-2772.	0.8	276
15	Safety and Efficacy of Weight Training in Recent Breast Cancer Survivors to Alter Body Composition, Insulin, and Insulin-Like Growth Factor Axis Proteins. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1672-1680.	1.1	269
16	The IGF system and breast cancer.. <i>Endocrine-Related Cancer</i> , 2001, 8, 197-209.	1.6	267
17	Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. <i>Nanomedicine</i> , 2008, 3, 83-91.	1.7	212
18	Crosstalk between the insulin-like growth factors and estrogens in breast cancer. , 2000, 5, 107-115.		210

#	ARTICLE	IF	CITATIONS
19	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2â€“Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3307-3329.	0.8	210
20	Effects of weight training on quality of life in recent breast cancer survivors. <i>Cancer</i> , 2006, 106, 2076-2083.	2.0	179
21	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. <i>Science Advances</i> , 2016, 2, e1601737.	4.7	175
22	Insulinâ€“like growth factor (IGF)â€“rescues breast cancer cells from chemotherapyâ€“induced cell death â€“ proliferative and antiâ€“apoptotic effects. <i>Breast Cancer Research and Treatment</i> , 1999, 56, 1-10.	1.1	174
23	Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?. <i>Journal of the National Cancer Institute</i> , 2012, 104, 975-981.	3.0	172
24	Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. <i>Journal of Endocrinology</i> , 1997, 152, 39-47.	1.2	169
25	Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 423-429.	1.0	149
26	Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 9994-10003.	1.6	147
27	A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. <i>Cancer Research</i> , 2003, 63, 627-35.	0.4	147
28	FKHR Binds the Insulin Response Element in the Insulin-Like Growth Factor Binding Protein-1 Promoter*. <i>Endocrinology</i> , 1999, 140, 3140-3146.	1.4	145
29	Forkhead Homologue in Rhabdomyosarcoma Functions as a Bifunctional Nuclear Receptor-interacting Protein with Both Coactivator and Corepressor Functions. <i>Journal of Biological Chemistry</i> , 2001, 276, 27907-27912.	1.6	144
30	A Dominant Negative Type I Insulin-like Growth Factor Receptor Inhibits Metastasis of Human Cancer Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 5017-5024.	1.6	142
31	Down-regulation of Type I Insulin-like Growth Factor Receptor Increases Sensitivity of Breast Cancer Cells to Insulin. <i>Cancer Research</i> , 2007, 67, 391-397.	0.4	138
32	Metabolite quantification and highâ€“field MRS in breast cancer. <i>NMR in Biomedicine</i> , 2009, 22, 65-76.	1.6	137
33	Adding in Vivo Quantitative 1H MR Spectroscopy to Improve Diagnostic Accuracy of Breast MR Imaging: Preliminary Results of Observer Performance Study at 4.0 T. <i>Radiology</i> , 2005, 236, 465-475.	3.6	135
34	Association of Event-Free and Distant Recurrenceâ€“Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1355.	3.4	119
35	Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. <i>Oncogene</i> , 2001, 20, 7318-7325.	2.6	118
36	Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. <i>Endocrine-Related Cancer</i> , 2011, 18, C19-C24.	1.6	117

#	ARTICLE	IF	CITATIONS
37	MicroRNAs Link Estrogen Receptor Alpha Status and Dicer Levels in Breast Cancer. <i>Hormones and Cancer</i> , 2010, 1, 306-319.	4.9	115
38	Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3-kinase Inhibition. <i>Molecular and Cellular Biology</i> , 2000, 20, 1489-1496.	1.1	113
39	Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. <i>Oncogene</i> , 2015, 34, 506-515.	2.6	112
40	Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. <i>Oncogene</i> , 2010, 29, 2517-2527.	2.6	111
41	Down-regulation of Insulin Receptor by Antibodies against the Type I Insulin-Like Growth Factor Receptor: Implications for Anti-Insulin-Like Growth Factor Therapy in Breast Cancer. <i>Cancer Research</i> , 2006, 66, 2391-2402.	0.4	110
42	Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. <i>British Journal of Cancer</i> , 2006, 95, 1220-1228.	2.9	109
43	Regulation of Insulin-Like Growth Factor-Binding Protein (IGFBP) Expression by Breast Cancer Cells: Use of IGFBP-1 as an Inhibitor of Insulin-like Growth Factor Action. <i>Journal of the National Cancer Institute</i> , 1992, 84, 1336-1341.	3.0	104
44	Characterization of Insulin-Like Growth Factor and Its Receptor and Binding Proteins in Transected Nerves and Cultured Schwann Cells. <i>Journal of Neurochemistry</i> , 1996, 66, 525-536.	2.1	102
45	Type I Insulin-like Growth Factor Receptor as a Therapeutic Target in Cancer: Figure 1.. <i>Cancer Research</i> , 2005, 65, 10123-10127.	0.4	100
46	Imaging in breast cancer: Magnetic resonance spectroscopy. <i>Breast Cancer Research</i> , 2005, 7, 149-52.	2.2	100
47	Targeting insulin-like growth factor pathways. <i>British Journal of Cancer</i> , 2006, 94, 465-468.	2.9	100
48	The IGF Pathway Regulates ER α through a S6K1-Dependent Mechanism in Breast Cancer Cells. <i>Molecular Endocrinology</i> , 2011, 25, 516-528.	3.7	99
49	Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer Treatment. <i>Cancer Research</i> , 2012, 72, 3372-3380.	0.4	99
50	Correlation of Insulin-Like Growth Factor-Binding Protein-3 Messenger RNA With Protein Expression in Primary Breast Cancer Tissues: Detection of Higher Levels in Tumors With Poor Prognostic Features. <i>Journal of the National Cancer Institute</i> , 1996, 88, 601-606.	3.0	97
51	Eliminating spurious lipid sidebands in 1H MRS of breast lesions. <i>Magnetic Resonance in Medicine</i> , 2002, 48, 215-222.	1.9	97
52	Insulin-like growth factor-I and cancer risk. <i>Growth Hormone and IGF Research</i> , 2004, 14, 261-269.	0.5	95
53	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. <i>Cancer Cell</i> , 2022, 40, 609-623.e6.	7.7	92
54	Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. <i>Journal of Cellular Biochemistry</i> , 1993, 52, 196-205.	1.2	90

#	ARTICLE	IF	CITATIONS
55	Insulin-like growth factors and breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 1995, 49, 415-421.	2.5	85
56	The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. <i>Oncogene</i> , 2010, 29, 251-262.	2.6	85
57	Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. <i>Oncogene</i> , 2000, 19, 4574-4581.	2.6	83
58	Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 251-261.	1.0	78
59	IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. <i>PLoS ONE</i> , 2015, 10, e0133152.	1.1	78
60	The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2911-2915.	3.2	77
61	Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. <i>Journal of Cellular Physiology</i> , 1993, 157, 229-236.	2.0	75
62	Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer. <i>Breast Cancer Research</i> , 2000, 2, 170-5.	2.2	75
63	Revisiting the IGF-1R as a breast cancer target. <i>Npj Precision Oncology</i> , 2017, 1, .	2.3	75
64	Water-fat MRI for assessing changes in bone marrow composition due to radiation and chemotherapy in gynecologic cancer patients. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 1578-1584.	1.9	73
65	STAT6 Mediates Interleukin-4 Growth Inhibition in Human Breast Cancer Cells. <i>Neoplasia</i> , 2002, 4, 324-331.	2.3	72
66	Minireview: Were the IGF Signaling Inhibitors All Bad?. <i>Molecular Endocrinology</i> , 2015, 29, 1549-1557.	3.7	72
67	A Randomized Controlled Trial of Green Tea Extract Supplementation and Mammographic Density in Postmenopausal Women at Increased Risk of Breast Cancer. <i>Cancer Prevention Research</i> , 2017, 10, 710-718.	0.7	72
68	Igf system components as prognostic markers in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1998, 47, 295-302.	1.1	70
69	Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. <i>Clinical Cancer Research</i> , 2003, 9, 2440-6.	3.2	70
70	Cloning, Chromosome Localization, Expression, and Characterization of an Src Homology 2 and Pleckstrin Homology Domain-containing Insulin Receptor Binding Protein hGrb10 ³ . <i>Journal of Biological Chemistry</i> , 1997, 272, 29104-29112.	1.6	69
71	MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1059-1069.	0.8	69
72	Identification of insulin-like growth factor binding proteins in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 1991, 18, 3-10.	1.1	68

#	ARTICLE	IF	CITATIONS
73	Atypical methylation of the interleukin-8 gene correlates strongly with the metastatic potential of breast carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13988-13993.	3.3	68
74	Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. New England Journal of Medicine, 2017, 377, 2287-2289.	13.9	68
75	Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells. Cancer Research, 2004, 64, 7479-7485.	0.4	67
76	Strain-specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. Cancer Letters, 1999, 144, 31-37.	3.2	65
77	The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opinion on Investigational Drugs, 2004, 13, 1569-1577.	1.9	65
78	Progesterone and Breast Cancer. Women's Health, 2008, 4, 151-162.	0.7	64
79	Multiple Signaling Pathways are Activated During Insulin-like Growth Factor-I (IGF-I) Stimulated Breast Cancer Cell Migration. Breast Cancer Research and Treatment, 2005, 93, 159-168.	1.1	63
80	Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. Breast Cancer Research, 2018, 20, 115.	2.2	63
81	FKHR Binds the Insulin Response Element in the Insulin-Like Growth Factor Binding Protein-1 Promoter. , 0, .		59
82	A Novel Human Insulin-Like Growth Factor I Messenger RNA is Expressed in Normal and Tumor Cells. Molecular Endocrinology, 1990, 4, 1914-1920.	3.7	57
83	Gene expression of the insulin-like growth factors and their receptors in cultured human retinal pigment epithelial cells. Molecular Brain Research, 1992, 12, 181-186.	2.5	57
84	Insulin-like growth factors in human breast cancer. Breast Cancer Research and Treatment, 1991, 18, S55-S62.	1.1	56
85	The insulin-like growth factor system as a target in breast cancer. Breast Cancer Research and Treatment, 1994, 32, 85-95.	1.1	55
86	Inhibitors of Insulin-like Growth Factor Signaling: A Therapeutic Approach for Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2006, 11, 27-39.	1.0	55
87	The insulin-like growth factor family of ligands, receptors, and binding proteins. Breast Cancer Research and Treatment, 1992, 22, 7-19.	1.1	54
88	Adenovirus-Mediated Gene Transfer of Herpes Simplex Virus Thymidine Kinase in an Ascites Model of Human Breast Cancer. Human Gene Therapy, 1996, 7, 1251-1257.	1.4	54
89	Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Research, 2002, 62, 4369-75.	0.4	54
90	Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Molecular Cancer Therapeutics, 2006, 5, 611-620.	1.9	53

#	ARTICLE	IF	CITATIONS
91	Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore. <i>British Journal of Cancer</i> , 2009, 101, 71-79.	2.9	50
92	MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 290-302.	1.9	49
93	I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 303-310.	0.5	49
94	Motility Response to Insulin-like Growth Factor-I (IGF-I) in MCF-7 Cells is Associated with IRS-2 Activation and Integrin Expression. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 161-170.	1.1	48
95	Mobile Phone Multilevel and Multimedia Messaging Intervention for Breast Cancer Screening: Pilot Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2017, 5, e154.	1.8	47
96	The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 1992, 22, 81-90.	1.1	46
97	Insulinlike Growth Factors in Human Malignancy. <i>Cancer Investigation</i> , 1991, 9, 443-454.	0.6	45
98	The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance. <i>Cancer and Metastasis Reviews</i> , 2003, 22, 327-336.	2.7	44
99	Omission of radiation therapy after breast-conserving surgery in the United States. <i>Cancer</i> , 2012, 118, 2004-2013.	2.0	43
100	IGF-I Regulates Redox Status in Breast Cancer Cells by Activating the Amino Acid Transport Molecule xC ⁺ . <i>Cancer Research</i> , 2014, 74, 2295-2305.	0.4	43
101	Validation of marrow fat assessment using noninvasive imaging with histologic examination of human bone samples. <i>Bone</i> , 2015, 72, 118-122.	1.4	42
102	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1654.	3.4	42
103	Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 277-285.	1.1	41
104	DNA adducts of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 4-aminobiphenyl are infrequently detected in human mammary tissue by liquid chromatography/tandem mass spectrometry. <i>Carcinogenesis</i> , 2012, 33, 124-130.	1.3	41
105	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€“Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	0.8	40
106	The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristics. <i>Cancer Causes and Control</i> , 2015, 26, 1405-1419.	0.8	38
107	Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. <i>Cancer Letters</i> , 1994, 77, 25-32.	3.2	37
108	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. <i>Nature Communications</i> , 2021, 12, 6428.	5.8	36

#	ARTICLE	IF	CITATIONS
109	The insulin-like growth factors and breast cancer " revisited. Breast Cancer Research and Treatment, 1998, 47, 197-199.	1.1	33
110	How does the estrogen receptor work?. Breast Cancer Research, 2002, 4, 62-4.	2.2	33
111	Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response <i>in vitro</i> and <i>in vivo</i> . Clinical Cancer Research, 2009, 15, 2840-2849.	3.2	33
112	Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Research and Treatment, 2010, 122, 585-590.	1.1	32
113	Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells. Oncogene, 2016, 35, 4235-4243.	2.6	32
114	Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. Breast Cancer Research and Treatment, 2017, 166, 541-547.	1.1	32
115	The insulin-like growth factor system as a treatment target in breast cancer. Seminars in Oncology, 2002, 29, 86-95.	0.8	32
116	Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. European Journal of Cancer, 1993, 29, 2015-2019.	1.3	31
117	Disrupting Insulin and IGF Receptor Function in Cancer. International Journal of Molecular Sciences, 2021, 22, 555.	1.8	31
118	Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. British Journal of Cancer, 1998, 77, 2138-2147.	2.9	30
119	BMP-binding protein twisted gastrulation is required in mammary gland epithelium for normal ductal elongation and myoepithelial compartmentalization. Developmental Biology, 2013, 373, 95-106.	0.9	30
120	Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL. JCO Precision Oncology, 2018, 2, 1-20.	1.5	30
121	Insulin-like growth factor-I and breast cancer therapy. Clinical Cancer Research, 2005, 11, 944s-50s.	3.2	30
122	Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vascular Health and Risk Management, 2015, 11, 591.	1.0	29
123	Longitudinal assessment of bone loss from diagnostic computed tomography scans in gynecologic cancer patients treated with chemotherapy and radiation. American Journal of Obstetrics and Gynecology, 2010, 203, 353.e1-353.e7.	0.7	28
124	Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Cancer Research and Treatment, 2012, 133, 117-126.	1.1	28
125	Use of dual-energy computed tomography to measure skeletal-wide marrow composition and cancellous bone mineral density. Journal of Bone and Mineral Metabolism, 2017, 35, 428-436.	1.3	28
126	A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patients. Bone, 2015, 73, 90-97.	1.4	27

#	ARTICLE	IF	CITATIONS
127	Introduction: IGFs and IGFBPs in the normal mammary gland and in breast cancer. , 2000, 5, 1-5.		26
128	The Influence of Therapeutic Radiation on the Patterns of Bone Marrow in Ovary-Intact and Ovariectomized Mice. PLoS ONE, 2012, 7, e42668.	1.1	26
129	Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cells. SpringerPlus, 2015, 4, 689.	1.2	26
130	A Tale of Two Receptors: Insulin and Insulin-Like Growth Factor Signaling in Cancer. Clinical Cancer Research, 2015, 21, 667-669.	3.2	26
131	Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds. Molecular Cancer Therapeutics, 2017, 16, 1324-1334.	1.9	26
132	EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice. Endocrine-Related Cancer, 2016, 23, 747-758.	1.6	25
133	Insulin-Like Growth Factors and Breast Cancer Therapy. Advances in Experimental Medicine and Biology, 2007, 608, 101-112.	0.8	25
134	Prognostic Indicators in Early Breast Cancer. American Journal of the Medical Sciences, 1993, 305, 176-182.	0.4	24
135	Phase II trial of 13-cis-retinoic acid plus interferon- γ in recurrent head and neck cancer. Investigational New Drugs, 1993, 11, 57-60.	1.2	23
136	Effects of a 9-month strength training intervention on insulin, insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-1, and IGFBP-3 in 30-50-year-old women. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1597-604.	1.1	23
137	Characterization of insulin-like growth factor binding proteins (IGFBP) and regulation of IGFBP-4 in bone marrow stromal cells. British Journal of Haematology, 1995, 90, 249-257.	1.2	22
138	Characterization of insulin-like growth factor binding proteins and regulation of IGFBP3 in human mesangial cells. Kidney International, 1996, 49, 1071-1078.	2.6	22
139	The α 2 and α 3 integrins are required for morphologic differentiation of an intestinal epithelial cell line. Surgery, 2003, 133, 429-437.	1.0	21
140	Insulin-Like Growth Factor (IGF)-I Controls Prostate Fibromuscular Development: IGF-I Inhibition Prevents Both Fibromuscular and Glandular Development in Eugonadal Mice. Endocrinology, 2007, 148, 1080-1088.	1.4	21
141	Progesterone Receptor-B Regulation of Insulin-Like Growth Factor- α Stimulated Cell Migration in Breast Cancer Cells via Insulin Receptor Substrate-2. Molecular Cancer Research, 2008, 6, 1491-1498.	1.5	21
142	Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells. Breast Cancer Research and Treatment, 2013, 139, 351-360.	1.1	21
143	Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials. Clinical Cancer Research, 2013, 19, 2817-2823.	3.2	21
144	Exogenous near-infrared fluorophores and their applications in cancer diagnosis: biological and clinical perspectives. Expert Opinion on Medical Diagnostics, 2011, 5, 241-251.	1.6	20

#	ARTICLE	IF	CITATIONS
145	Insulin-Like Growth Factors, Insulin, and Growth Hormone Signaling in Breast Cancer: Implications for Targeted Therapy. <i>Endocrine Practice</i> , 2014, 20, 1214-1221.	1.1	20
146	Green Tea Catechin Extract Supplementation Does Not Influence Circulating Sex Hormones and Insulin-Like Growth Factor Axis Proteins in a Randomized Controlled Trial of Postmenopausal Women at High Risk of Breast Cancer. <i>Journal of Nutrition</i> , 2019, 149, 619-627.	1.3	20
147	Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis. <i>Breast Cancer</i> , 2021, 28, 618-629.	1.3	20
148	Effects of Insulin-Like Growth Factor-1 Receptor Inhibition in Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2006, 82, 996-1002.	0.7	19
149	Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. <i>Breast Cancer Research</i> , 2017, 19, 107.	2.2	19
150	40 YEARS OF IGF1: Anti-insulin-like growth factor therapy in breast cancer. <i>Journal of Molecular Endocrinology</i> , 2018, 61, T61-T68.	1.1	19
151	IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells. <i>Growth Hormone and IGF Research</i> , 1999, 9, 280-289.	0.5	18
152	Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. <i>Seminars in Oncology</i> , 2003, 30, 125-132.	0.8	17
153	Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 291-299.	1.1	17
154	Of Mice and (Wo)Men: Is This Any Way to Test a New Drug?. <i>Journal of Clinical Oncology</i> , 2008, 26, 830-832.	0.8	17
155	The insulin-like growth factor system as a treatment target in breast cancer. <i>Seminars in Oncology</i> , 2002, 29, 86-95.	0.8	16
156	Are the insulin-like growth factors relevant to cancer?. <i>Growth Hormone and IGF Research</i> , 2001, 11, 339-345.	0.5	15
157	Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage IIâ€“III Breast Cancer: A Multicenter Value Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1510-1517.	2.3	15
158	Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. <i>Breast Cancer Research and Treatment</i> , 2006, 96, 217-225.	1.1	14
159	Longitudinal FDG-PET Revealed Regional Functional Heterogeneity of Bone Marrow, Site-Dependent Response to Treatment and Correlation with Hematological Parameters. <i>Journal of Cancer</i> , 2015, 6, 531-537.	1.2	14
160	Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells. <i>Neoplasia</i> , 2016, 18, 100-110.	2.3	14
161	Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation. <i>Hormones and Cancer</i> , 2017, 8, 219-229.	4.9	14
162	Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells. <i>Hormones and Cancer</i> , 2018, 9, 371-382.	4.9	14

#	ARTICLE	IF	CITATIONS
163	Is the Type I Insulin-Like Growth Factor Receptor a Therapeutic Target in Endometrial Cancer?: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 6323-6325.	3.2	13
164	Adaptive Trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development. <i>Journal of Clinical Oncology</i> , 2012, 30, 4584-4586.	0.8	13
165	A Dual-Radioisotope Hybrid Whole-Body Micro-Positron Emission Tomography/Computed Tomography System Reveals Functional Heterogeneity and Early Local and Systemic Changes Following Targeted Radiation to the Murine Caudal Skeleton. <i>Calcified Tissue International</i> , 2014, 94, 544-552.	1.5	13
166	⁶⁴ Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor. <i>Molecular Pharmaceutics</i> , 2016, 13, 3747-3755.	2.3	13
167	Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL. <i>Cancer Research</i> , 2016, 76, CT042-CT042.	0.4	13
168	Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0150564.	1.1	13
169	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 131.	2.3	13
170	Targeting IGF-1R: at a crossroad. <i>Oncology</i> , 2011, 25, 535-6; discussion 551.	0.4	13
171	The Influence of Therapeutic Radiation on the Patterns of Bone Remodeling in Ovary-Intact and Ovariectomized Mice. <i>Calcified Tissue International</i> , 2013, 92, 372-384.	1.5	12
172	Yin Yang Gene Expression Ratio Signature for Lung Cancer Prognosis. <i>PLoS ONE</i> , 2013, 8, e68742.	1.1	12
173	eIF4E Threshold Levels Differ in Governing Normal and Neoplastic Expansion of Mammary Stem and Luminal Progenitor Cells. <i>Cancer Research</i> , 2015, 75, 687-697.	0.4	12
174	Advances in insulin-like growth factor biology and -directed cancer therapeutics. <i>Advances in Cancer Research</i> , 2020, 147, 229-257.	1.9	12
175	In vitro Sensitivity Testing of Human Bladder Cancers and Cell Lines to TP-40, a Hybrid Protein with selective Targeting and Cytotoxicity. <i>Journal of Urology</i> , 1993, 150, 1950-1955.	0.2	11
176	Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine. <i>AAPS Journal</i> , 2012, 14, 1-9.	2.2	11
177	Spatial and Temporal Fracture Pattern in Breast and Gynecologic Cancer Survivors. <i>Journal of Cancer</i> , 2015, 6, 66-69.	1.2	11
178	Pharmacokinetic profile of recombinant human insulin-like growth factor binding protein-1 in athymic mice. <i>Biomedicine and Pharmacotherapy</i> , 1996, 50, 154-157.	2.5	10
179	Targeting the insulin-like growth factor axis as a cancer therapy. <i>Future Oncology</i> , 2006, 2, 101-110.	1.1	10
180	Skeletal Remodeling Following Clinically Relevant Radiation-Induced Bone Damage Treated with Zoledronic Acid. <i>Calcified Tissue International</i> , 2012, 90, 40-49.	1.5	10

#	ARTICLE	IF	CITATIONS
181	Can the insulin-like growth factors regulate breast cancer growth?. Breast Cancer Research and Treatment, 1992, 22, 3-5.	1.1	9
182	Insulin-like Growth Factor Binding Protein Expression in Human Retinal Pigment Epithelial Cells. Annals of the New York Academy of Sciences, 1993, 692, 265-267.	1.8	8
183	Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. SpringerPlus, 2015, 4, 32.	1.2	8
184	Recent advances in neoadjuvant therapy for breast cancer. Faculty Reviews, 2021, 10, 2.	1.7	8
185	Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer. Endocrinology, 2021, 162, .	1.4	8
186	Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL. , 2016, , .		8
187	Interaction between insulin-like growth factor-I and insulin-like growth factor-binding proteins in TC-1 stromal cells. Journal of Endocrinology, 1996, 149, 519-529.	1.2	7
188	The IGF System in Mammary Development and Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 351-352.	1.0	7
189	Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system. Lung Cancer, 2007, 58, 196-204.	0.9	6
190	Estrogen-related receptor alpha: an orphan finds a family. Breast Cancer Research, 2012, 14, 309.	2.2	6
191	Neoadjuvant as Future for Drug Development in Breast Cancerâ€™Response. Clinical Cancer Research, 2016, 22, 269-269.	3.2	6
192	Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance bystander effect in breast cancer cells. Breast Cancer Research and Treatment, 2000, 62, 109-115.	1.1	4
193	Adaptor Proteins as Targets for Cancer Prevention. Cancer Prevention Research, 2010, 3, 263-265.	0.7	4
194	Generic entry of aromatase inhibitors and pharmaceutical access: Initiation of hormonal therapy, timeliness of initiation, and drug choice. Research in Social and Administrative Pharmacy, 2021, 17, 1588-1595.	1.5	4
195	Hormonal Therapy Drug Switching, Out-of-Pocket Costs, and Adherence Among Older Women With Breast Cancer. Journal of the National Cancer Institute, 2022, 114, 1029-1035.	3.0	3
196	Use of Insulin-like Growth Factor-I Gene Expression to Distinguish Between Breast and Ovarian Cancer. American Journal of the Medical Sciences, 1994, 307, 108-111.	0.4	2
197	The Type I IGF Receptor as a Target for Breast Cancer Therapy. Breast Disease, 2003, 17, 115-124.	0.4	2
198	How to Train Your Biomarker. Clinical Cancer Research, 2010, 16, 3091-3093.	3.2	2

#	ARTICLE	IF	CITATIONS
199	Arterial elasticity in testicular cancer survivors.. Journal of Clinical Oncology, 2014, 32, 9604-9604.	0.8	2
200	Insulin-like growth factor binding proteins: Potential inhibitors of cancer cell growth. Drugs of the Future, 1994, 19, 477.	0.0	2
201	Insulin-like Growth Factor Binding Protein Expression in SH-SY5Y Neuroblastoma Cells. Annals of the New York Academy of Sciences, 1993, 692, 262-264.	1.8	1
202	Crosstalk Between Insulin-like Growth Factor (IGF) and Epidermal Growth Factor (EGF) Receptors. , 2008, , 147-160.		1
203	Hawai'i's role to increase public participation in health research. Hawaii Medical Journal, 2008, 67, 4-6.	0.4	1
204	Targeting the insulin-like growth factor receptor. Clinical Advances in Hematology and Oncology, 2009, 7, 452-4.	0.3	1
205	EGF receptor: new trick for an old dog?. Breast Cancer Research, 2001, 3, 1.	2.2	0
206	Should diabetic women with breast cancer have their own intervention studies?. Endocrine-Related Cancer, 2012, 19, C13-C17.	1.6	0
207	Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas. Biology of Blood and Marrow Transplantation, 2014, 20, S184-S185.	2.0	0
208	CCR 20th Anniversary Commentary: Stayin' Aliveâ€™Antiapoptotic Proteins and Breast Cancer. Clinical Cancer Research, 2015, 21, 665-666.	3.2	0
209	IGF1R- and ROR1-Specific Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas. Biology of Blood and Marrow Transplantation, 2015, 21, S52-S53.	2.0	0
210	Type I Insulin-Like Growth Factor Receptor. , 2017, , 823-829.		0
211	IGF 1 and IGF 2. , 2017, , 739-743.		0
212	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. Endocrinology, 2018, , 765-785.	0.1	0
213	Role of Insulin-Like Growth Factor Receptors in Cancer Signaling. , 2019, , 283-288.		0
214	Abstract PS6-05: Impact of body mass index on pathological complete response after neoadjuvant chemotherapy: Results from the I-SPY 2 trial. , 2021, , .		0
215	The Emerging Role of the Fetal Insulin Receptor in Hormone-refractory Breast Cancer. Endocrinology, 2021, 162, .	1.4	0
216	Insulin-Like Growth Factors and Endocrine Neoplasia. , 2000, , 193-214.		0

#	ARTICLE	IF	CITATIONS
217	Basic Principles of Antineoplastic Therapies. , 2010, , 707-715.		0
218	IGF System and Breast Cancer. , 2012, , 73-84.		0
219	Type I Insulin-Like Growth Factor Receptor. , 2013, , 1-7.		0
220	Utilizing RNA-Seq to Define Phytochemical-Induced Alterations in Insulin and IGF-Regulated Transcriptomes. Methods in Pharmacology and Toxicology, 2014, , 189-204.	0.1	0
221	Cloning, chromosome localization, expression, and characterization of an Src homology 2 and pleckstrin homology domain-containing insulin receptor binding protein hGrb10 ³ .. Journal of Biological Chemistry, 1998, 273, 4288.	1.6	0
222	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. Endocrinology, 2016, , 1-21.	0.1	0
223	Cyclin E in breast cancer. New England Journal of Medicine, 2003, 348, 1063-4; author reply 1063-4.	13.9	0
224	Breast disease. Introduction. Breast Disease, 2003, 17, 1-2.	0.4	0